Cartesian Therapeutics Inc (NAS:RNAC)
$ 28 3.69 (15.02%) Market Cap: 498.29 Mil Enterprise Value: 344.29 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

Selecta Biosciences Inc Phase I SEL-399 AAV Data Results Call Transcript

Nov 08, 2021 / 01:30PM GMT
Release Date Price: $118.8 (+0.51%)
Operator

Good day, and welcome to the Selecta Biosciences Phase I SEL-399 top line data conference call. (Operator Instructions) Please note this event is being recorded.

I'd now like to turn the conference over to Kevin Tan. Please go ahead.

Kevin Tan
Selecta Biosciences, Inc. - CFO

Thank you, and good morning. During this call, we will discuss the top line data report from the Phase I clinical trial of SEL-399, empty capsid in healthy volunteers. The press release reporting the results and today's presentation are available in the Investors and Media section of our website, www.selectabio.com. And a copy of this presentation will be available with the current form on Form 8-K, which we filed this morning with the Securities and Exchange Commission, or SEC.

Joining me today are Dr. Carsten Brunn, our President and Chief Executive Officer; Dr. Peter G. Traber, our Chief Medical Officer; and Dr. Kei Kishimoto, our Chief Scientific Officer.

During today's call, we will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot